Relay Therapeutics Insider Sells $11,441 in Stock

Peter Rahmer, a Relay Therapeutics insider, sold over 1,300 shares of the company's stock.

Jan. 29, 2026 at 7:15pm

Got story updates? Submit your updates here. ›

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 1,354 shares of the company's stock on Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $11,441.30. Following the sale, Rahmer still owns 276,610 shares of Relay Therapeutics stock, valued at $2,337,354.50.

Why it matters

Insider transactions, such as stock sales, can provide insights into how company insiders view the stock's valuation and future prospects. While a single insider sale does not necessarily indicate a negative outlook, it is still noteworthy when a company insider reduces their ownership stake.

The details

In addition to the 1,354 shares sold by Peter Rahmer, other Relay Therapeutics insiders also made sales around the same time period. CFO Thomas Catinazzo sold 15,515 shares, and insider Donald A. Bergstrom sold 21,581 shares. These transactions resulted in decreases in the insiders' ownership percentages of the company.

  • On January 27th and 28th, 2026, Relay Therapeutics insiders made these stock sales.

The players

Peter Rahmer

An insider at Relay Therapeutics who sold 1,354 shares of the company's stock.

Thomas Catinazzo

The Chief Financial Officer of Relay Therapeutics who sold 15,515 shares of the company's stock.

Donald A. Bergstrom

An insider at Relay Therapeutics who sold 21,581 shares of the company's stock.

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

The takeaway

The recent insider sales at Relay Therapeutics, while not necessarily indicating a negative outlook, do suggest that company insiders may view the current stock valuation as an opportune time to reduce their ownership stakes. Investors should closely monitor any further insider transaction activity and consider it alongside the company's overall financial performance and strategic direction.